AUTHORS
Elias Jabbour, MD, Dennis Dong Hwan Kim, MD, PhD2, Paul Koller, MD3, Vivian G. Oehler, MD4, Maria R. Baer, MD5, Anthony Michael Hunter, MD6, Huanshan Guo, MD7, Zhihong Yang, PhD8, Tommy Fu, PhD9, Dajun Yang, MD, PhD10, Yifan Zhai, MD, PhD11, Hagop Kantarjian, MD12
AFFILIATIONS
1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada
3 Department of Hematology & Hematopoietic Cell Transplantation in the Division of Leukemia, City of Hope National Medical Center, Duarte, California, United States
4 Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, Washington, United States
5 University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
6 Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, United States
7 Guangzhou Healthquest Pharma Co., Ltd., Guangzhou, China
8 Ascentage Pharma Group Inc., Rockville, Maryland, United States
9 Ascentage Pharma Group Inc., Rockville, Maryland, United States
10 Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China, Ascentage Pharma Group Inc., Rockville, Maryland, United States, Department of Experimental Research, State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
11 Ascentage Pharma Group Inc., Rockville, Maryland, United States, Guangzhou Healthquest Pharma Co., Ltd., Guangzhou, China
12 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background
Patients with advanced Ph+ BCP ALL and CML-LBP continue to have poor outcomes despite the availability of BCR::ABL1 tyrosine kinase inhibitors (TKIs). Chemotherapy-free regimens including the bispecific T-cell engager antibody blinatumomab have demonstrated meaningful clinical activity; however, achieving durable deep molecular responses remains an unmet need. Olverembatinib is a novel third-generation BCR::ABL1 TKI with activity against T315I and other resistance mutations. This study evaluated olverembatinib combined with blinatumomab in patients with relapsed/refractory Ph+ BCP ALL or CML-LBP.
Methods
Eligible patients with Ph+ BCP ALL or CML-LBP received olverembatinib (30 mg or 40 mg, every other day) in combination with blinatumomab (per label use). Eligibility criteria enabled enrollment of patients who were either intolerant, relapsed, or minimal residual disease (MRD) positive; therefore, some patients were enrolled despite being MRD negative. Efficacy (complete response [CR], molecular responses, MRD negativity) and safety were reported based on the data cutoff date of July 21, 2026.
Results
A total of 17 patients were treated, including 16 with Ph+ BCP ALL and 1 with CML-LBP. The median age was 47 years (range, 23-68); 23.5% (4/17) of patients had the BCR::ABL1 T315I mutation; and 58.8% (10/17) of patients had prior blinatumomab exposure. At baseline, 52.9% (9/17) of patients were MRD positive, and 41.2% (7/17) had discontinued their last TKI due to lack of efficacy. The median treatment duration was ~17 weeks, and the median follow-up was 40.9 weeks. Among evaluable patients (e.g., those who had reached their first efficacy assessment and did not have responses at baseline), molecular responses were rapid and deep. Major molecular response (MMR) was achieved in 80.0% (12/15), and molecular response 4.0 (MR4.0) in 60.0% (9/15). Among 13 evaluable patients, CR was achieved in 84.6% (11/13), and CR was achieved by cycle 1 in 76.9% (10/13). MRD negativity (at 10-4 sensitivity by flow cytometry) was observed in 83.3% (10/12) of evaluable patients, with 58.3% (7/12) achieving MRD negativity by cycle 1. The median time to reach MR4.0 or better, CR, and MRD negativity was approximately 41 days each. Responses were durable, with no documented loss of CR, MRD negativity, or MR4.0-or-deeper responses among responding patients during the follow-up period. After achieving response, patients either continued olverembatinib-based maintenance therapy, proceeded to allogeneic stem cell transplantation, or received subsequent cellular therapy according to investigator discretion. The patient with CML-LBP achieved a treatment response. The combination regimen demonstrated efficacy; however, discontinuation of blinatumomab was mainly due to completion of the planned treatment course following achievement of response, rather than lack of efficacy. Grade ≥3 treatment-emergent adverse events (TEAEs) were reported in 76.5% (13/17) of patients. Frequently observed grade ≥3 TEAEs included neutropenia (23.5%), as well as creatine kinase increase, pneumonia, sepsis, sinusitis, and thrombocytopenia (in 11.8% each). Serious TEAEs occurred in 52.9% of patients; pneumonia and sepsis were the most common, each occurring in 11.8%. Olverembatinib-related TEAEs occurred in 52.9% of patients, and grade ≥3 olverembatinib-related TEAEs occurred in 35.3%, primarily neutropenia (17.6%). This safety profile was manageable and consistent with previous reports.
Conclusions
Olverembatinib in combination with blinatumomab demonstrated high rates of CR, MRD negativity, and rapid deep molecular response in patients with Ph+ BCP ALL and CML-LBP, who were predominantly blinatumomab exposed and had T315I mutations. The regimen showed a manageable safety profile, supporting further development of this chemotherapy-free regimen for patients with Ph+ BCP ALL or CML-LBP.
DISCLOSURES
Elias Jabbour, MD: Ascentage - Honoraria; Pfizer - Honoraria; Takeda - Honoraria; Amgen Inc. - Honoraria; Taiho - Honoraria; Novartis - Honoraria; TGRX Pharmaceuticals - Honoraria; Adaptive Biotechnologies - Honoraria; AbbVie - Honoraria; Gilead/Kite - Honoraria; TERN - Honoraria; Autolus - Honoraria; Amgen Inc. - Research Funding; AbbVie - Research Funding; Autolus - Research Funding; Takeda - Research Funding; Pfizer - Research Funding; Taiho - Research Funding; TGRX Pharmaceuticals - Research Funding; Gilead/Kite - Research Funding; Ascentage - Research Funding; Allotera - Research Funding; Novartis - Research Funding; Adaptive Biotechnologies - Research Funding; TERN - Research Funding; Amgen Inc. - Consultancy (Includes expert testimony); Allotera - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); TGRX Pharmaceuticals - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); Gilead/Kite - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Taiho - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); TERN - Consultancy (Includes expert testimony)